A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepato-biliary-pancreatic sciences"
DOI: 10.1002/jhbp.1026
Abstract: BACKGROUND We advocated carbohydrate antigen (CA) 19-9 ≥ 150 U/mL and tumor size ≥ 30 mm as "high-risk markers" for predicting unresectability among patients with radiologically resectable (R) or borderline resectable (BR) pancreatic ductal adenocarcinoma… read more here.
Keywords: risk markers; risk; resectable borderline; high risk ... See more keywords
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24872
Abstract: Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 Day 1, 5‐FU 2400 mg/m2 × 48 h IV, peg‐filgrastim 6 mg SQ day 3, every 14 days) has substantial… read more here.
Keywords: systemic therapy; resectable pancreatic; primary systemic; mfolfirinox ... See more keywords
Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer
Sign Up to like & getrecommendations! Published in 2018 at "Abdominal Radiology"
DOI: 10.1007/s00261-018-1647-4
Abstract: PurposeTo evaluate the prognostic value of preoperative 18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with potentially resectable pancreatic cancer.MethodsThe study included 103 consecutive patients with potentially resectable pancreatic cancer who underwent preoperative… read more here.
Keywords: potentially resectable; resectable pancreatic; pancreatic cancer; patients potentially ... See more keywords
Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis
Sign Up to like & getrecommendations! Published in 2019 at "Surgery Today"
DOI: 10.1007/s00595-019-01786-w
Abstract: The aim of the study was to evaluate the effect of neoadjuvant therapy on long-term survival in patients with resectable and borderline resectable pancreatic cancer. A meta-analysis was conducted using the reported randomized, controlled trials… read more here.
Keywords: resectable borderline; long term; analysis; resectable pancreatic ... See more keywords
Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-020-00417-9
Abstract: Background Patients with borderline resectable pancreatic cancer are at high risk of incomplete resection with upfront surgery. Currently, no standard induction chemotherapy regimen exists for these patients. Both FOLFIRINOX (5-FU, irinotecan, & oxaliplatin) and gemcitabine… read more here.
Keywords: patients borderline; folfirinox gnp; resectable pancreatic; pancreatic cancer ... See more keywords
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Journal of Gastroenterology"
DOI: 10.1007/s12328-021-01480-w
Abstract: Pancreatic cancer is the fourth leading cause of cancer-related death in Japan. Pancreatic cancer is categorized as resectable, borderline resectable, or unresectable based on the degree of adjacent vascular invasion and the presence of distant… read more here.
Keywords: resectable pancreatic; pancreatic cancer; neoadjuvant chemotherapy; necrotic enteritis ... See more keywords
Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.01.015
Abstract: After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases… read more here.
Keywords: multimodal treatment; resectable pancreatic; treatment; adenocarcinoma ... See more keywords
Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-52167-9
Abstract: The effectiveness of neoadjuvant therapy (NAT) remains unclear in resectable pancreatic cancer (PC) as compared with upfront surgery (US). The aim of this study was to investigate the survival gain of NAT over US in… read more here.
Keywords: surgery; analysis; resectable pancreatic; pancreatic cancer ... See more keywords
Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-53271-6
Abstract: Circulating tumor DNA (ctDNA) is a promising prognostic biomarker in various cancers. Due to the high recurrence rate of resectable pancreatic ductal adenocarcinoma (PDAC), effective strategies for prognostic stratification are necessary. Yet, for resectable PDAC,… read more here.
Keywords: ctdna; resectable pancreatic; circulating tumor; tumor dna ... See more keywords
Neoadjuvant chemo(radio)therapy in upfront resectable pancreatic cancer – can we stratify patients better in the future?
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2100226
Abstract: Pancreatic ductal adenocarcinoma is associated with one of the lowest survival rates among cancers and recently a 5year survival still below 5% was reported [1]. Despite that pancreatic cancer is fairly infrequent, the lack of… read more here.
Keywords: cancer; pancreatic cancer; resectable pancreatic; therapy ... See more keywords
Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery
Sign Up to like & getrecommendations! Published in 2021 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.1944662
Abstract: Abstract Background Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison with upfront surgery (US).… read more here.
Keywords: rfs; resectable pancreatic; rate; borderline resectable ... See more keywords